Pharmacokinetics, metabolism, and saliva output during transidermal and extended-release oral oxybutynin administration in healthy subjects
Pharmacokinetics, metabolism, and saliva output during transidermal and extended-release oral oxybutynin administration in healthy subjects
复制标题
DOI：
10.4065/78.6.696
复制
发表时间：
2003-06-01
影响因子：
8.9
通讯作者：
Sanders, SW
中科院分区：
文献类型：
--
作者：
Appell, RA;Chancellor, MB;Sanders, SW
目的：比较两种缓释奥昔布宁治疗方法的药代动力学和不良反应动力学。受试者和方法：2001年10月15日至11月6日，13名健康受试者（7男6女）参加了一项随机、双向交叉研究，研究对象为透皮给药（Oxytrol，3.9 mg/d）和缓释口服给药（Ditropan XL，10 mg）奥昔布宁。采集了多份血液和唾液样本。评估药代动力学参数和总唾液排出量。统计学分析包括95%置信区间，配对t检验，方差分析，和线性region.Results：稳态血药浓度后，第一次经皮给药后，第二次缓释口服剂量。透皮和口服缓释治疗期间奥昔布宁浓度-时间曲线下面积的平均值+/- SD相当，分别为10.8+/-2.4 vs 9.2+/-3.3 ng。h（-1）。mL（-1）。然而，经皮给药后的曲线下面积比（N-去乙基奥昔布宁/奥昔布宁）（1.2+/-03）显著降低（P
Objective: To compare the pharmacokinetics and adverse effect dynamics of 2 modified-release oxybutynin treatments.Subjects and Methods: Between October 15 and November 6,2001,13 healthy subjects (7 men and 6 women) participated in a randomized, 2-way crossover study of transdermal (Oxytrol, 3.9 mg/d) and extended-release oral (Ditropan XL,10 mg) oxybutynin. Multiple blood and saliva samples were collected. Pharmacokinetic parameters and total salivary output were assessed. Statistical analyses included 95% confidence intervals, paired t test, analysis of variance, and linear regression.Results: Steady-state plasma concentrations were achieved after the first transdermal application and after the second extended-release oral dose. Mean +/- SD 24-hour oxybutynin areas under the concentration-time curve were comparable during transdermal and oral extended-release treatments, 10.8+/-2.4 vs 9.2+/-3.3 ng . h(-1) . mL(-1), respectively. However, the ratio of area under the curve (N-desethyloxybutynin/oxybutynin) after transdermal administration (1.2+/-03) was significantly lower (P